SERODUS approaches collaborations and licensing deals with the aim of reflecting the needs and aligning the contributions of both partners.
Are you looking for drug candidates in type 2 diabetes and its comorbidities, for opportunities that address diseases of unmet medical need and have the potential to revolutionize the standard of care?
Serodus’ business model is based on out-licensing its pipeline programs to international pharma, specialty pharma and expert biotech companies after showing “proof-of-concept”.
We welcome inquiries from potential partners wishing to discuss potential collaborations with us.
Partnerships are an important part of Serodus growth strategy.
To inquire about partnering opportunities, please send an email to Jürgen Langhärig, VP Business Development at: Juergen.email@example.com
What makes Serodus an attractive partner?
Serodus is a virtual drug-development company and therefore are we “assets” oriented.
Management has a proven track record of bringing new compounds to the market and of closing major partnering agreements.
Our seasoned management team develops our drug candidates through a network of contract research organizations and contract manufacturers.
If you partner with us early, you can influence the optimal development strategy.
Our project directors are passionate about our development programs and working with us is rewarding.
Acquisitions and in-licensing
Serodus’ strategy is to expand our product pipeline through acquisitions and by entering into in-licensing arrangements with biotech companies and universities.
Serodus acquired its current assets through the acquisition of Phlogo (SER130 and SER140), patent assignment of SER100 from Zealand Pharma and the in-licensing of SER150 from Evolva.
Where to meet us:
List of events where you can meet us:
- CEO & Investor Conference, February 12-13, 2018. New York, USA
- BioEquity Europe, May 14-16, 2018. Ghent, Belgium
- ADA, June 22 - 26, 2018, Orlando, Florida